Skip to main content
Home / Current Drug Targets, Volume 14, Number 12
Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.

Publisher: Bentham Science Publishers

More about this publication?
Volume 14, Number 12, 2013

Articles

Free Content Editorial (Thematic Issue: New Mechanisms and Targets for IBD Therapy: Translational Gastroenterology Comes of Age)
pp. 1377-1378(2)
Authors: Danese, Silvio; Peyrin-Biroulet, Laurent

Favourites:
ADD

Anti-IL-12/23 in Crohn's Disease: Bench and Bedside
pp. 1379-1384(6)
Authors: Niederreiter, Lukas; Erik Adolph, Timon; Kaser, Arthur

Favourites:
ADD

Janus Kinase Inhibition with Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment
pp. 1385-1391(7)
Authors: Vuitton, Lucine; Koch, Stephane; Peyrin-Biroulet, Laurent

Favourites:
ADD

Clinical Strategies for the Blockade of IL-18 in Inflammatory Bowel Diseases
pp. 1392-1399(8)
Authors: Kanai, Takanori; Kamada, Nobuhiko; Hisamatsu, Tadakazu

Favourites:
ADD

TGF-Beta Signaling Manipulation as Potential Therapy for IBD
pp. 1400-1404(5)
Authors: Marafini, Irene; Zorzi, Francesca; Codazza, Sefora; Pallone, Francesco; Monteleone, Giovanni

Favourites:
ADD

Review: New Anti-Cytokines for IBD: What is in the Pipeline?
pp. 1405-1420(16)
Authors: Scharl, Michael; R. Vavricka, Stephan; Rogler, Gerhard

Favourites:
ADD

Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?
pp. 1421-1432(12)
Authors: Oikonomopoulos, Angelos; K. van Deen, Welmoed; W. Hommes, Daniel

Favourites:
ADD

Vedolizumab for the Treatment of IBD: A Selective Therapeutic Approach Targeting Pathogenic a4b7 Cells
pp. 1433-1443(11)
Authors: Jovani, Manol; Danese, Silvio

Favourites:
ADD

Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside
pp. 1444-1452(9)
Authors: Jovani, Manol; Fiorino, Gionata; Danese, Silvio

Favourites:
ADD

Cell Therapies for IBD: What Works?
pp. 1453-1459(7)
Authors: Ricart, Elena; Jauregui-Amezaga, Aranzazu; Ordas, Ingrid; Pino, Susana; M. Ramirez, Anna

Favourites:
ADD

Sealing the Broken Barrier in IBD: Intestinal Permeability, Epithelial Cells and Junctions
pp. 1460-1470(11)
Authors: Fries, Walter; Belvedere, Alessandra; Vetrano, Stefania

Favourites:
ADD

Is There Still a Room for Azathioprine Monotherapy in Inflammatory Bowel Disease?
pp. 1471-1479(9)
Authors: Bourrier, Anne; Seksik, Philippe; Cosnes, Jacques

Favourites:
ADD

Methotrexate: Should We Start Using it in Clinical Practice?
pp. 1480-1489(10)
Authors: Miheller, Pal; S. Kiss, Lajos; Mandel, Michael; L. Lakatos, Peter

Favourites:
ADD

Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease
pp. 1490-1500(11)
Authors: Bamias, Giorgos; J. Clark, David; Rivera-Nieves, Jesus

Favourites:
ADD

PPAR-Gamma in Ulcerative Colitis: A Novel Target for Intervention
pp. 1501-1507(7)
Authors: Bertin, Benjamin; Dubuquoy, Laurent; Colombel, Jean-Frederic; Desreumaux, Pierre

Favourites:
ADD

Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target
pp. 1508-1521(14)
Authors: Allocca, Mariangela; Jovani, Manol; Fiorino, Gionata; Schreiber, Stefan; Danese, Silvio

Favourites:
ADD

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content